|
New safeguards for patient safety as Falsified Medicines Directive comes into force |
Medicines for Europe |
11 Feb 2019 |
Health & Consumers |
|
No further excuse to delay digital regulatory infrastructure for medicines after COVID-19 pandemic |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
Now or never: Europe must seize the Pharma Legislation opportunity to ensure patient access to continuous innovation for existing medicines |
Medicines for Europe |
07 Nov 2023 |
Health & Consumers |
|
Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing |
Medicines for Europe |
07 Oct 2020 |
Health & Consumers |
|
Off patent medicines essential for a fairer, healthier, and sustainable Europe says President Christoph Stoller |
Medicines for Europe |
30 Apr 2021 |
Health & Consumers |
|
Off-patent medicines industry marks 30 years of delivering public health impact |
Medicines for Europe |
12 Jun 2024 |
Health & Consumers |
|
Off-patent medicines ready to drive pharma policy reform for equitable access, availability and security of medicines supply |
Medicines for Europe |
15 Jun 2023 |
Health & Consumers |
|
Oncology, the new era for biosimilar medicines |
Medicines for Europe |
08 Sep 2017 |
Health & Consumers |
|
Open borders that prioritise essential goods key to medicines supply in Europe |
Medicines for Europe |
02 Jun 2021 |
Health & Consumers |
|
Orphan and paediatric reform should strive to improve access to medicine for rare disease patients and children |
Medicines for Europe |
30 Jul 2021 |
Health & Consumers |
|
Parliament compromise on pharmaceutical legislation accelerates much needed reform |
Medicines for Europe |
19 Mar 2024 |
Health & Consumers |
|
Parliament’s balanced stand on Unitary SPC regulation rewards innovation via an efficient Unitary SPC system that protects against access to medicines delays |
Medicines for Europe |
28 Feb 2024 |
InfoSociety |
|
Parliament’s Health Committee (ENVI) introduces constructive amendments to SPC Manufacturing waiver vote in its official opinion to the Parliament’s Legal Committee (JURI). |
Medicines for Europe |
28 Nov 2018 |
Health & Consumers |
|
Parliament’s Trade Committee votes for jobs and access to medicines with a comprehensive SPC Manufacturing Waiver! |
Medicines for Europe |
04 Dec 2018 |
Health & Consumers |
|
Patients should benefit from greater access under new patent package proposals |
Medicines for Europe |
28 Apr 2023 |
Health & Consumers |
|
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies |
Medicines for Europe |
17 Nov 2022 |
Health & Consumers |
|
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition |
Medicines for Europe |
27 Oct 2022 |
Health & Consumers |
|
Protecting health: Active generic and biosimilar policies central to EU pharmaceutical strategy |
Medicines for Europe |
03 Mar 2020 |
Health & Consumers |
|
Reaction to EU Pharmaceutical legislation: Timely and equitable access for patients and security of supply essential for reform |
Medicines for Europe |
27 Apr 2023 |
Health & Consumers |
|
Ready to drive access to medicines |
Medicines for Europe |
24 Jul 2019 |
Health & Consumers |
|
Reformed incentives system promises better patient access in Europe |
Medicines for Europe |
11 Jun 2024 |
Health & Consumers |
|
Regulatory reforms critical to improve patient access to medicines |
Medicines for Europe |
24 Jan 2022 |
Health & Consumers |
|
Report identifies 9 key ingredients to improve access to medicines in the hospital setting |
Medicines for Europe |
08 Oct 2019 |
Health & Consumers |
|
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come |
Medicines for Europe |
18 Jan 2018 |
Health & Consumers, InfoSociety |
|
Repurposing: a golden opportunity for patient centric health investment in Europe |
Medicines for Europe |
06 Apr 2022 |
Health & Consumers |
|
Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers |
Medicines for Europe |
12 Oct 2018 |
Health & Consumers |
|
Smart Pharmacovigilance Essential for Patient Safety |
Medicines for Europe |
29 Jan 2020 |
Health & Consumers |
|
Smart policies will encourage more critical medicines manufacturing in Europe |
Medicines for Europe |
26 Feb 2021 |
Health & Consumers |
|
Smart reform of EU pharma and IP legislation key to boosting access to essential medicines |
Medicines for Europe |
30 Jun 2022 |
Health & Consumers |
|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
04 Feb 2021 |
Health & Consumers |
